Heights Capital Management’s Grace Therapeutics GRCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
– Sell
-1,281
Closed -$63K – 76
2019
Q1
$63K Buy
+1,281
New +$63.2K 0.06% 39

Other funds holding GRCE

Heights Capital Management's GRCE Position: Q2 2019 in Review

Heights Capital Management sold out of Grace Therapeutics (GRCE) in Q2 2019, closing a stake of 1,281 shares — an estimated $63K sold.

Heights Capital Management first reported a position in GRCE in Q1 2019 and held it in 1 quarter. The position peaked at $63K in Q1 2019. 13 funds tracked by Wall St. Rank hold GRCE as of Q2 2019.

  • Heights Capital Management reported no remaining Grace Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Heights Capital Management sold 1,281 Grace Therapeutics shares in Q2 2019, an estimated $63K.
  • Heights Capital Management first reported a position in Grace Therapeutics in Q1 2019 and held it in 1 quarter.
  • Heights Capital Management's Grace Therapeutics position peaked at $63K in Q1 2019.
  • 13 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2019.

Based on Heights Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.